ZEAL.CO · PEAD ↑ 40
Zealand Pharma reported Q1 2026 EPS of DKK -5.58 on 2026-05-07, beating the consensus of DKK -9.16 by DKK 3.58 (+39.1%).
Zealand Pharma reported Q1 2026 EPS of DKK -5.58 on 2026-05-07, beating the consensus of DKK -9.16 by DKK 3.58 (+39.1%).
Print-day reaction was +9.5% versus the prior close, a sharp re-rating on the EPS beat. The overnight gap to the T+1 open added a marginal +0.1%, suggesting the after-hours session offered no meaningful fade or continuation. Over days 1–3, the stock drifted –1.5%, giving back a modest slice of the initial surge without reversing it. Cumulative abnormal return of +6.0% versus SPY.US places this firmly in PEAD long territory; the drift sustains the initial reaction, and the documented pattern holds through 2026-08-04.